William Waddill Sells 9,000 Shares of Protagonist Therapeutics (NASDAQ:PTGX) Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William Waddill sold 9,000 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $117.94, for a total transaction of $1,061,460.00. Following the transaction, the director owned 7,825 shares in the company, valued at approximately $922,880.50. This represents a 53.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Protagonist Therapeutics Stock Up 0.4%

PTGX stock traded up $0.48 during trading on Thursday, hitting $122.63. 1,037,824 shares of the company’s stock traded hands, compared to its average volume of 743,077. The firm has a market capitalization of $7.89 billion, a P/E ratio of -67.75 and a beta of 1.85. The business has a fifty day simple moving average of $103.70 and a two-hundred day simple moving average of $94.76. Protagonist Therapeutics, Inc. has a 1 year low of $49.38 and a 1 year high of $126.25.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. The company had revenue of $56.37 million during the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%. On average, equities research analysts predict that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Farther Finance Advisors LLC lifted its stake in shares of Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after buying an additional 156 shares during the period. Greenline Wealth Management LLC acquired a new position in shares of Protagonist Therapeutics in the 4th quarter valued at $27,000. EverSource Wealth Advisors LLC raised its stake in Protagonist Therapeutics by 138.9% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock worth $36,000 after acquiring an additional 314 shares during the last quarter. Osaic Holdings Inc. raised its stake in Protagonist Therapeutics by 79.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,185 shares of the company’s stock worth $65,000 after acquiring an additional 525 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its position in Protagonist Therapeutics by 222.4% during the 4th quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock worth $83,000 after acquiring an additional 656 shares during the period. Institutional investors and hedge funds own 98.63% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on PTGX. Wedbush raised their price objective on Protagonist Therapeutics from $112.00 to $118.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Barclays increased their price target on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a research report on Thursday, March 19th. Citigroup restated an “outperform” rating on shares of Protagonist Therapeutics in a report on Wednesday, May 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $110.00 price objective on shares of Protagonist Therapeutics in a research report on Wednesday, May 6th. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of Protagonist Therapeutics in a research note on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $115.21.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.